IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment
Open Access
- 6 April 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (11), 2368-2379
- https://doi.org/10.1158/0008-5472.can-19-3108
Abstract
Pharmacologic IRE1α kinase inhibition reverses ultrastructural distension of the ER, normalizes the tumor vasculature, and remodels the cellular TME attenuating TNBC growth in mice.Other Versions
Funding Information
- Howard Hughes Medical Institute (N/A)
This publication has 60 references indexed in Scilit:
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomesNature Medicine, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stressNature, 2011
- IRE1α Kinase Activation Modes Control Alternate Endoribonuclease Outputs to Determine Divergent Cell FatesCell, 2009
- The unfolded protein response signals through high-order assembly of Ire1Nature, 2008
- The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004Cancer, 2008
- Structure of the Dual Enzyme Ire1 Reveals the Basis for Catalysis and Regulation in Nonconventional RNA SplicingCell, 2008
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinaseCell, 1993